Kazia (ASX: KZA) commences fifth trial of GDC-0084 with leading US cancer centre

Highlights

  • Kazia Therapeutics has announced that Memorial Sloan Kettering Cancer Center in New York will investigate the potential use of GDC-0084 for cancer that has spread to the brain.
  • The new trial will investigate whether GDC-0084 has the potential to enhance the effects of radiotherapy as treatment for patients with solid tumour brain metastases.
  • The trial will involve 18-30 patients over a period of two years bringing the total number of ongoing trials with GDC-0084 to five.

Australian biotechnology company Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), has announced that Memorial Sloan Kettering Cancer Center (MSK) in New York will investigate the potential use of Kazia’s investigational new drug, GDC-0084. The drug will be investigated in combination with radiotherapy in phase I clinical trial for cancer that has spread to the brain.

Research shows up to 30% of patients with metastatic cancer will develop secondary tumours in the brain. Despite the best care utilising radiotherapy as treatment, 30-50% of patients will progress within a year.

The new trial will investigate whether GDC-0084 has the potential to enhance the effects of radiotherapy as treatment for patients with solid tumour brain metastases along with leptomeningeal metastases. It is testing the hypothesis that GDC-0084 will assist in radiotherapy resistance. In recent animal models of some brain cancers, activation of the PI3K pathway has contributed to radiotherapy resistance. Implementation of GDC-0084 is used as a PI3K inhibitor that crosses the blood-brain barrier in an attempt to reduce radiotherapy resistance.

 

About Kazia Therapeutics Limited

Kazia Therapeutics Limited (ASX: KZA, NASDAQ: KZIA) is an innovative oncology-focused biotechnology company, based in Sydney, Australia. Our pipeline includes two clinical-stage drug development candidates, and we are working to develop therapies across a range of oncology indications.

Register Interest